Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study.
Kang WangHongfei ZhuHongming YuYuqiang ChengYan-Jun XiangZhangjun ChengYang LiTao LiDongxu WangZhenyu ZhuShu-Qun ChengPublished in: Journal of oncology (2023)
TACE combined with atezo/bev showed encouraging efficacy and an acceptable safety profile, making it a promising treatment option for patients with BCLC B HCC beyond the up-to-seven criteria, which will be further investigated in a prospective single-arm trial.